ArticleAnnals of thoracic surgery short reports2026
The Role of Resection for Stage II Small Cell Lung Cancer.
Article in Annals of thoracic surgery short reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We sought to determine whether surgery provides a survival benefit for patients with stage II small cell lung cancer (SCLC). Methods: We compared patients with stage II SCLC who underwent surgical resection with those who did not using the National Cancer Database from 2004-2020. Groups were propensity-matched and overall survival difference was compared with Kaplan-Meier analysis. Results: We identified 6797 patients with stage II SCLC who received treatment. Only 10% underwent surgery. Ninety percent of patients underwent nonsurgical treatment, with the most common treatment being chemotherapy combined with radiation (n = 4610). After propensity matching, the surgical cohort had higher overall survival: 79.1% vs 70.6% at 1 year and 33.2% vs 20.4% at 5 years ( Conclusions: In a propensity-matched analysis of patients in the National Cancer Database with stage II SCLC, we found sustained survival benefit for patients whose treatment included surgery. This survival benefit was present for both N0 and N1 disease, but most pronounced for N0 patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.